Capital keeps flowing into ASX Biotech shares in 2021

What is driving capital inflow into ASX biotech shares?

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date.

Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain, one observes that this total increases to over $1 billion, according to today's Australian Financial Review.

Here, we examine just what is driving this recent trend in capital inflows towards ASX Biotech shares.

What is behind the surge in inflows to ASX Biotech shares this year?

There has been a spate of capital raised for ASX Biotech shares this year, such as Imugene Limited (ASX: IMU), Immutep Ltd (ASX: IMM) and Aroa Biosurgery Ltd (ASX: ARX).

For instance, Imugene recently "completed an upsized $95 million offer", issuing ~300 million additional shares at a price of 30 cents apiece.

Aroa also "banked $53 million in a placement and share purchase plan [SPP]" earlier this week to eligible investors at $1.165 per share. $5 million of this total is sought from the SPP.

There appears to be "four big reasons behind the recent flurry of [capital] raising" trends that have occurred this year.

These include the establishment of new equity-focused healthcare investment funds, outsized returns in the broad sector, and a cluster of collaborations with big pharmaceutical companies.

Moreover, it also appears the biotech sector "has the flavour of the month for investors", as per the Financial Review.

Bell Potter Securities analyst Darren Craike was quoted saying:

A lot of generalist funds are looking for alpha [above market return] in their portfolios…so many have started to gravitate to healthcare where there have been some exceptional returns in the last two to three years.

Moreover, the trends look set to continue for the time being, with a number of pre-IPO's on the cards.

To illustrate, Tissue Repair which is a regenerative medicine and aesthetic dermatology company, plans on "targeting a $25 million raise" via listing this year.

Additionally, upcoming biotech names Triad Lifesciences and Vitfrafy Lifesciences "are also confirmed to be pursuing listings" this year.

ASX Biotech shares snapshot

The basket of ASX Biotech shares contained within the S&P / ASX 200 Index (ASX: XJO) has provided a return of 116% since March of this year.

This select group has outpaced the overall broad index, which has posted a return of ~12.5% this year to date.

Such returns help to explain the attractiveness of ASX Biotech shares for Australian investors at the current standing.

Should you invest $1,000 in Aroa Biosurgery Limited right now?

Before you buy Aroa Biosurgery Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Aroa Biosurgery Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

More on Share Market News

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Technology Shares

Goldman Sachs says this ASX 200 stock can rise 20%+

Let's see why the broker believes this stock could deliver market-beating returns.

Read more »

Dog with a shoe in its mouth.
Opinions

This ASX income stock just cut its dividend: I think it's time to invest

This business is paying a smaller dividend, but I think that makes it more attractive.

Read more »

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Share Market News

Income investors: These Australian dividend shares are raising payouts again

It's time for a pay rise!

Read more »

A male ASX 200 broker wearing a blue shirt and black tie holds one hand to his chin with the other arm crossed across his body as he watches stock prices on a digital screen while deep in thought
Share Market News

5 things to watch on the ASX 200 on Tuesday

Here's what Aussie investors can expect from the benchmark index today.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rocky but positive start to the week's trading this Monday.

Read more »

Business people discussing project on digital tablet.
Share Market News

6 ASX 200 shares bought up by directors last week

It was a busy week for ASX directors last week.

Read more »

Three people jumping cheerfully in clear sunny weather.
52-Week Highs

5 ASX 200 stocks hitting new 52-week highs today

These stocks are pushing higher today despite the shaky market...

Read more »

An engineer takes a break on a staircase and looks out over a huge open pit coal mine as the sun rises in the background.
Share Market News

One of these insiders just made a $1 million BHP share buy

These management figures seem to think BHP is cheap right now...

Read more »